Cardiac Radiation Dose, Cardiac Events, and Survival in Locally Advanced NSCLC
Megan DalyMegan Daly The standard of care for fit patients with unresectable, locally advanced (LA-) NSCLC is concurrent chemoradiation (CRT) followed by consolidation durvalumab. However, thoracic radiation (RT) for lung cancer […] Read more
Brain Metastases in NSCLC: Is Delaying Upfront Radiation a Viable Option?
By Arya Amini, MD, and Chad G. Rusthoven, MD Posted: August 19, 2020 Approximately 10% of patients diagnosed with metastatic NSCLC present with brain metastases, and another 30% develop brain […] Read more
PCI Decreases the Risk of Brain Metastases in Patients with Locally Advanced NSCLC
By Elizabeth Gore, MD Posted: May 27, 2019 IN REFERENCE TO: De Ruysscher D, Dingemans AC, Praag J, et al. Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell […] Read more
By John Armstrong, MD, FRCPI, DABR, FFRRCSI Posted: December 2018 RTOG 0214, a phase III randomized trial, is the biggest trial to date testing prophylactic cranial irradiation (PCI) in locally […] Read more
2018 ASTRO Guideline for Palliative Thoracic Radiation Therapy for NSCLC: The Balance Between Curative and Palliative Radiotherapy
By Shalini K. Vinod, MBBS, MD Posted: October 2018 The standard of care for patients with inoperable stage III NSCLC is curative radiotherapy and concurrent chemotherapy.1 However, there are numerous […] Read more
Living in the “Gray Zone”: Entering a New Age in Radiation Therapy for Patients with Lung Cancer
Posted: October 2018 Patients with stage III or more advanced lung cancer tend to be older and less healthy than patients with other stage III cancers. Because of this, selection […] Read more
By Leah Lawrence Posted: June 2018 The use of trimodality therapy—the combination of chemoradiotherapy followed by surgery—remains controversial for patients with locally advanced cN2-N3 NSCLC. According to the National Comprehensive […] Read more
Patients with EGFR Mutation Should Postpone Brain Radiation for CNS Metastases: Pro and Con
By Pranshu Mohindra, MD, MBBS, DABR®, Lecia Sequist, MD, and Laurie E. Gaspar, MD, MBA Posted: December 2017 Since the initial approval of erlotinib, an oral tyrosine kinase inhibitor (TKI), […] Read more
Utility and Controversies Surrounding Use of New Techniques in Radiotherapy
By Suresh Senan, MRCP, FRCR, PhD Posted: December 2017 Improved delivery of radiotherapy has contributed to the recent changes in guidelines for patients with lung cancer. The clinical impact of […] Read more
By Cynthia L. Kryder, MS, CCC-Sp Posted: October 2017 For patients who present with inoperable, locally advanced lung cancer, photon-based chemoradiation remains the standard of care. Despite advanced radiation-delivery techniques, […] Read more